Healthy Participants
Conditions
Keywords
AMG 691, Respiratory Tract Diseases, Asthma, Lung Diseases
Brief summary
The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants
Interventions
DRUGAMG 691
AMG 691 will be administered subcutaneously
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female participants, 18 to 60 years of age. * First-generation Chinese ancestry (born in China, Hong Kong, Taiwan, or Macau with 2 Chinese parents and 4 Chinese grandparents) or first-generation Japanese ancestry (born in Japan with 2 Japanese parents and 4 Japanese grandparents). * Body mass index (BMI) 18.0 to 30.0 kg/m\^2 (inclusive) and body weight ≥40 kg. * In good general health based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations. * Female participants must not be pregnant or breastfeeding. * Participants of reproductive potential must agree to follow protocol-specified contraception requirements. * Willing to maintain usual diet and physical activity regimen throughout study participation.
Exclusion criteria
* Clinically significant medical condition, disease, or abnormal finding that could interfere with study participation or interpretation of results. * Clinically significant ECG abnormalities * Clinically significant abnormal blood pressure or pulse rate at screening/check-in. * History of malignancy (except adequately treated in situ cervical cancer or non-melanoma skin cancer \>5 years before dosing). * Deep vein thrombosis or pulmonary embolism within 3 months prior to check-in. * History of hypersensitivity/anaphylaxis to biologic therapies, mammalian-derived products, or AMG 691 excipients. * Active, chronic, recurrent, or unresolved infection; history of severe infection requiring intravenous (IV) antibiotics within the past 3 years. * Positive or indeterminate QuantiFERON-TB Gold test. * Untreated or unresolved helminth parasitic infection. * History of immunodeficiency. * Receipt of live or live-attenuated vaccines within 12 weeks before check-in or planned during the study. * Estimated glomerular filtration rate (eGFR) \<70 mL/min/1.73 m\^2. * Alanine Aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, or direct bilirubin \>1.5 × Upper Limit Normal (ULN). * Positive screening tests for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection. * Use of prohibited prescription, over-the-counter, herbal, vitamin, or dietary supplement products within 30 days (or 5 half-lives) before enrollment, unless approved by the investigator. * History of illicit drug use within 1 year, positive drug screen, or unwillingness to abstain from illicit drugs/cannabinoids during the study. * Use of tobacco or nicotine-containing products within 6 months prior to check-in. * History of alcohol abuse or excessive alcohol consumption. * History of non-suicidal self-injury within 5 years or unstable major depressive disorder/other severe psychiatric disorder within 2 years. * Participation in another investigational drug study within 90 days (or 5 half-lives) prior to check-in. * Previous exposure to AMG 691. * Recent donation of blood, plasma, or platelets. * Any participant considered unsuitable by the investigator or unwilling to comply with study restrictions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Observed Serum Concentration (Cmax) of AMG 691 | Day 1 up to Day 154 |
| Area Under the Serum Concentration Time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of AMG 691 | Up to Day 154 |
| Area Under the Serum concentration Time Curve from Time Zero to Infinity (AUC0-inf) of AMG 691 | Up to Day 154 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Day 1 to end of trial (approximately 154 days) |
| Number of Participants with Serious Adverse Events (SAEs) | From screening (Day -28) up to end of trial (approximately 154 days) |
| Number of Participants Who Develop Anti-AMG 691 Antibodies | Up to Day 154 |
Countries
United States
Contacts
CONTACTAmgen Call Center
STUDY_DIRECTORMD
Amgen
Outcome results
None listed